Related Experiment Video

Updated: Jun 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New anticoagulants for the prevention of venous thromboembolism

Cecilia Becattini1, Alessandra Lignani, Giancarlo Agnelli

  • 1Internal and Cardiovascular, Medicine and Stroke Unit, University of Perugia, Italy. cecila.becattini@unipg.it

Drug Design, Development and Therapy
|June 10, 2010
PubMed

Insights

New anticoagulant drugs, including anti-Xa and antithrombin agents, offer improved efficacy and safety for preventing thromboembolic diseases. These novel oral anticoagulants show promise for individualized therapy.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Anticoagulant drugs are crucial for managing thromboembolic diseases.
  • Existing anticoagulants have limitations, necessitating new drug development.
  • Ideal anticoagulants should be effective, safe, simple to use, and broadly applicable.

Purpose of the Study:

  • To review the development and potential of novel anticoagulant agents.
  • To highlight advancements in direct anti-Xa and antithrombin inhibitors.
  • To discuss the future of individualized anticoagulant therapy.

Main Methods:

  • Review of clinical development phases for new anticoagulants.
  • Analysis of pharmacological profiles (pharmacokinetics and pharmacodynamics).
  • Evaluation of efficacy and safety data from clinical trials.

Main Results:

  • Several novel oral anticoagulants (e.g., rivaroxaban, dabigatran, apixaban) are in clinical development or use.
  • These agents target Factor Xa or antithrombin with selective action.
  • Promising efficacy and safety profiles have been observed across various conditions.

Conclusions:

  • Novel anticoagulants demonstrate potential to overcome limitations of current therapies.
  • Fixed-dose oral administration simplifies usage.
  • Pharmacokinetic and pharmacodynamic variability may enable personalized anticoagulant treatment strategies.
Keywords:
anticoagulant therapyanticoagulantsantithrombotic therapydirect thrombin inhibitorsfactor Xa inhibitors

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...